US equities |
SPCX $166.89 ▲+4.99% NVDA $236.21 ▲+0.97% MU $1,062.77 ▼-1.13% TSLA $377.14 ▲+1.77% MSFT $524.37 ▲+1.32% SNDK $1,704.81 ▼-0.88% INTC $117.22 ▼-1.77% META $742.50 ▲+1.98%
FinancialContent

Merus N.V. - Common Shares (NQ:MRUS)

90.00 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merus N.V. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
From Merus N.V.
Via GlobeNewswire
News headline image
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
Poster presentation: Monday, April 8, 2024, 9:00 am-12:30 p.m. PT 
From Merus N.V.
Via GlobeNewswire
News headline image
Expert Ratings for Merus ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Merus ↗
 
Via Benzinga
News headline image
10 Analysts Have This to Say About Merus ↗
 
Via Benzinga
News headline image
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
News headline image
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
News headline image
Where Merus Stands With Analysts ↗
 
Via Benzinga
News headline image
Expert Ratings for Merus ↗
 
Via Benzinga
News headline image
Analyst Expectations for Merus's Future ↗
 
Via Benzinga
News headline image
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24 
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
News headline image
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
News headline image
Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Business Update Conference Call
From Merus N.V.
Via GlobeNewswire
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
From Merus N.V.
Via GlobeNewswire
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The... 
Via FinancialNewsMedia
News headline image
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst ↗
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients  
Via Benzinga
News headline image
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 21, 2023 ↗
 
Via Benzinga
News headline image
Merus Announces Pricing of Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
News headline image
Merus N.V. Announces Proposed Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023
From Merus N.V.
Via GlobeNewswire
News headline image
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
From Merus N.V.
Via GlobeNewswire
News headline image
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
From Merus N.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >